[go: up one dir, main page]

PE20120773A1 - Anillos triciclicos fusionados sustituidos como inhibidores del virus de hepatitis c - Google Patents

Anillos triciclicos fusionados sustituidos como inhibidores del virus de hepatitis c

Info

Publication number
PE20120773A1
PE20120773A1 PE2011001719A PE2011001719A PE20120773A1 PE 20120773 A1 PE20120773 A1 PE 20120773A1 PE 2011001719 A PE2011001719 A PE 2011001719A PE 2011001719 A PE2011001719 A PE 2011001719A PE 20120773 A1 PE20120773 A1 PE 20120773A1
Authority
PE
Peru
Prior art keywords
hepatitis
fused tricyclic
alkyl
tricyclic rings
virus inhibitors
Prior art date
Application number
PE2011001719A
Other languages
English (en)
Inventor
Leping Li
Min Zhong
Original Assignee
Presidio Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Presidio Pharmaceuticals Inc filed Critical Presidio Pharmaceuticals Inc
Publication of PE20120773A1 publication Critical patent/PE20120773A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA (I) DONDE: D PUEDE ESTAR AUSENTE O ES -CH2CH2-, -O-, ENTRE OTROS; A Y E SON CADA UNO O, CH2, -CH=, -CH2-CH2-, ENTRE OTROS; Ra ES OH, CN, NO2, HALOGENO, ALQUILO C1-12, ENTRE OTROS; r ES 0-3; Rc, Rd y Re SON CADA UNO H, ALQUILO C1-C8, HETEROALQUILO C1-C8, ARALQUILO Y UN ANILLO C4-8 U OPCIONALMENTE Rc Y Rd SE UNEN PARA FORMAR UN HETEROCICLO C4-C8 QUE ES OPCIONALMENTE FUSIONADO A OTRO ANILLO HETEROCICLO O HETEROARILO C3-C5; Y e Y' SON CADA UNO C, N; Z Y Z' SON CADAUNO H, ALQUILO C1-C8, HETEROALQUILO C1-C8, CICLOALQUILO, HETEROCICLO, ENTRE OTROS; W Y W' SE SELECCIONAN DEL GRUPO OXAZOL, IMIDAZOL, ISOXAZOL, 1,2,4-TRIAZOL, ENTRE OTROS. SE REFIERE ADEMAS A UNA COMPOSICION FARMACEUTICA. DICHO COMPUESTO ES UN INHIBIDOR DE LA PROTEINA 5A NO ESTRUCTURAL (5ANE) DEL VIRUS DE LA HEPATITIS C
PE2011001719A 2009-03-27 2010-03-25 Anillos triciclicos fusionados sustituidos como inhibidores del virus de hepatitis c PE20120773A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16434209P 2009-03-27 2009-03-27
US21488309P 2009-04-28 2009-04-28

Publications (1)

Publication Number Publication Date
PE20120773A1 true PE20120773A1 (es) 2012-07-19

Family

ID=42781523

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011001719A PE20120773A1 (es) 2009-03-27 2010-03-25 Anillos triciclicos fusionados sustituidos como inhibidores del virus de hepatitis c

Country Status (19)

Country Link
US (1) US9150554B2 (es)
EP (1) EP2410843A4 (es)
JP (1) JP5735482B2 (es)
KR (1) KR20110131312A (es)
CN (1) CN102427726B (es)
AR (1) AR076164A1 (es)
AU (1) AU2010229795A1 (es)
BR (1) BRPI1012282A2 (es)
CA (1) CA2755658A1 (es)
CL (1) CL2011002377A1 (es)
CO (1) CO6450600A2 (es)
EA (1) EA201190224A1 (es)
IL (1) IL215202A0 (es)
MX (1) MX2011010132A (es)
PE (1) PE20120773A1 (es)
SG (1) SG174883A1 (es)
TW (1) TW201038560A (es)
WO (1) WO2010111534A1 (es)
ZA (1) ZA201107753B (es)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102245604A (zh) 2008-12-23 2011-11-16 雅培制药有限公司 抗病毒化合物
CA2740193A1 (en) 2008-12-23 2010-07-01 Abbott Laboratories Anti-viral compounds
US8314135B2 (en) 2009-02-09 2012-11-20 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole antivirals
US8394968B2 (en) 2009-02-17 2013-03-12 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8188132B2 (en) 2009-02-17 2012-05-29 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
US8242156B2 (en) 2009-02-17 2012-08-14 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
US8673954B2 (en) 2009-02-27 2014-03-18 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
US8101643B2 (en) 2009-02-27 2012-01-24 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
US9765087B2 (en) 2009-02-27 2017-09-19 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
US8507522B2 (en) 2009-03-06 2013-08-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
NZ595410A (en) 2009-03-27 2013-12-20 Merck Sharp & Dohme Inhibitors of hepatitis c virus replication
US9150554B2 (en) 2009-03-27 2015-10-06 Presidio Pharmaceuticals, Inc. Fused ring inhibitors of hepatitis C
US20190127365A1 (en) 2017-11-01 2019-05-02 Merck Sharp & Dohme Corp. Inhibitors of hepatitis c virus replication
US8796466B2 (en) 2009-03-30 2014-08-05 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TW201038559A (en) 2009-04-09 2010-11-01 Bristol Myers Squibb Co Hepatitis C virus inhibitors
US8143414B2 (en) 2009-04-13 2012-03-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2010120935A1 (en) 2009-04-15 2010-10-21 Abbott Laboratories Anti-viral compounds
JP2012526834A (ja) * 2009-05-12 2012-11-01 シェーリング コーポレイション ウイルス疾患治療に有用な縮合型三環式アリール化合物
PE20120509A1 (es) 2009-05-13 2012-05-09 Gilead Sciences Inc Derivados 9,9 difluoro-9h-fluoreno que tiene actividad antiviral
US8211928B2 (en) 2009-05-29 2012-07-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8138215B2 (en) 2009-05-29 2012-03-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
US8716454B2 (en) 2009-06-11 2014-05-06 Abbvie Inc. Solid compositions
PL2455376T3 (pl) 2009-06-11 2015-06-30 Abbvie Bahamas Ltd Związki heterocykliczne jako inhibitory wirusa zapalenia wątroby typu C (HCV)
US8221737B2 (en) 2009-06-16 2012-07-17 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8609648B2 (en) 2009-07-02 2013-12-17 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
EP2454254A2 (en) 2009-07-16 2012-05-23 Vertex Pharmaceuticals Incorporated Benzimidazole analogues for the treatment or prevention of flavivirus infections
DK2464645T3 (en) 2009-07-27 2017-10-23 Gilead Sciences Inc CONDENSED, HETEROCYCLIC COMPOUNDS AS IRON CHANNEL MODULATORS
CN102480971B (zh) 2009-09-04 2014-11-26 杨森制药公司 化合物
US8815928B2 (en) 2009-09-11 2014-08-26 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8927709B2 (en) 2009-09-11 2015-01-06 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8759332B2 (en) 2009-09-11 2014-06-24 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8703938B2 (en) 2009-09-11 2014-04-22 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US9156818B2 (en) 2009-09-11 2015-10-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8822700B2 (en) 2009-09-11 2014-09-02 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US20110269956A1 (en) * 2009-11-11 2011-11-03 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110274648A1 (en) 2009-11-11 2011-11-10 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110281910A1 (en) 2009-11-12 2011-11-17 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US8653070B2 (en) 2009-12-14 2014-02-18 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN104530079B (zh) * 2009-12-18 2017-10-20 北京凯因科技股份有限公司 C型肝炎病毒复制的新型抑制剂
US8362020B2 (en) 2009-12-30 2013-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8933110B2 (en) 2010-01-25 2015-01-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
WO2011091417A1 (en) 2010-01-25 2011-07-28 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
US8623814B2 (en) 2010-02-23 2014-01-07 Enanta Pharmaceuticals, Inc. Antiviral agents
US8178531B2 (en) 2010-02-23 2012-05-15 Enanta Pharmaceuticals, Inc. Antiviral agents
WO2011109037A1 (en) 2010-03-04 2011-09-09 Enanta Pharmaceuticals, Inc. Combination pharmaceutical agents as inhibitors of hcv replication
JP2013522375A (ja) 2010-03-24 2013-06-13 バーテックス ファーマシューティカルズ インコーポレイテッド フラビウイルス感染を処置または予防するためのアナログ
WO2011127350A1 (en) 2010-04-09 2011-10-13 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
EP2575819A4 (en) 2010-06-04 2013-11-27 Enanta Pharm Inc INHIBITORS OF HEPATITIS C VIRUS
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
US8703759B2 (en) 2010-07-02 2014-04-22 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
WO2012003642A1 (en) * 2010-07-09 2012-01-12 Merck Sharp & Dohme Corp. Fused tricyclic compounds and use thereof for treating viral diseases
AU2011286276A1 (en) * 2010-07-26 2013-01-24 Merck Sharp & Dohme Corp. Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases
WO2012021704A1 (en) 2010-08-12 2012-02-16 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
WO2012050918A2 (en) 2010-09-29 2012-04-19 Presidio Pharmaceutical, Inc. Tricyclic fused ring inhibitors of hepatitis c
EP2621279B1 (en) 2010-09-29 2018-04-04 Merck Sharp & Dohme Corp. Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases
SG10201509456SA (en) 2010-11-17 2015-12-30 Gilead Pharmasset Llc Antiviral compounds
RU2452735C1 (ru) 2010-11-30 2012-06-10 Александр Васильевич Иващенко Замещенные азолы, противовирусный активный компонент, фармацевтическая композиция, способ получения и применения
US8552047B2 (en) 2011-02-07 2013-10-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2012122716A1 (en) * 2011-03-17 2012-09-20 Merck Sharp & Dohme Corp. Tetracyclic xanthene derivatives and methods of use thereof for treatment of viral diseases
PL2707361T3 (pl) 2011-05-10 2018-01-31 Gilead Sciences Inc Skondensowane związki heterocykliczne stosowane jako modulatory kanału sodowego
US9546160B2 (en) 2011-05-12 2017-01-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
CN103687489A (zh) 2011-05-18 2014-03-26 埃南塔制药公司 制备5-氮杂螺[2.4]庚烷-6-甲酸及其衍生物的方法
NO3175985T3 (es) 2011-07-01 2018-04-28
TWI622583B (zh) 2011-07-01 2018-05-01 基利科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
JP2014520822A (ja) 2011-07-09 2014-08-25 スンシネ ルアケ プハルマ カンパニー リミテッド Ｃ型肝炎ウイルス阻害剤としてのスピロ化合物
TW201321373A (zh) 2011-08-08 2013-06-01 Glaxosmithkline Llc 化合物
WO2013030750A1 (en) 2011-09-01 2013-03-07 Lupin Limited Antiviral compounds
UA116087C2 (uk) 2011-09-16 2018-02-12 Гіліад Фармассет Елелсі Композиція для лікування вірусу гепатиту c
AP2013006877A0 (en) 2011-11-16 2013-05-31 Gilead Sciences Inc Antiviral compounds
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9073943B2 (en) 2012-02-10 2015-07-07 Lupin Limited Antiviral compounds with a dibenzooxaheterocycle moiety
US20130309196A1 (en) 2012-05-16 2013-11-21 Gilead Sciences, Inc. Antiviral compounds
CN103420991B (zh) * 2012-05-17 2017-07-07 乳源东阳光药业有限公司 作为丙型肝炎抑制剂的吡咯烷衍生物及其在药物中的应用
TWI610916B (zh) 2012-08-03 2018-01-11 廣東東陽光藥業有限公司 作爲丙型肝炎抑制劑的橋環化合物及其在藥物中的應用
CN103848821B (zh) 2012-11-29 2016-10-12 广东东阳光药业有限公司 作为丙型肝炎抑制剂的螺环化合物、药物组合物及它们的用途
US9802949B2 (en) 2012-11-29 2017-10-31 Sunshine Lake Pharma Co., Ltd. Fused ring compounds as hepatitis C virus inhibitors, pharmaceutical compositions and uses thereof
WO2014110687A1 (en) 2013-01-16 2014-07-24 Merck Sharp & Dohme Corp. Thiazolyl-substitued tetracyclic compounds and methods of use thereof for treatment of viral diseases
MY172166A (en) 2013-01-31 2019-11-15 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
RU2507201C1 (ru) 2013-02-07 2014-02-20 Александр Васильевич Иващенко Алкил [(s)-1-((s)-2-{5-[4-(4-{2-[(s)-1-((s)-2-метоксикарбониламино-3-метил-бутирил)-пирролидин-2-ил]-3н-имидазол-4-ил}-бута-1,3-диинил)-фенил]-1н-имидазол-2-ил}-пирролидин-1-карбонил)-2-метил-пропил]-карбамат нафталин-1,5-дисульфонат, фармацевтическая композиция, лекарственное средство, способ лечения вирусных заболеваний
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
US20150023913A1 (en) 2013-07-02 2015-01-22 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
EP3021845A1 (en) 2013-07-17 2016-05-25 Bristol-Myers Squibb Company Combinations comprising biphenyl derivatives for use in the treatment of hcv
SG11201600919UA (en) 2013-08-27 2016-03-30 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
EP3089757A1 (en) 2014-01-03 2016-11-09 AbbVie Inc. Solid antiviral dosage forms
US9738629B2 (en) 2014-01-23 2017-08-22 Sunshine Lake Pharma Co., Ltd. Bridged ring compounds as Hepatitis C virus inhibitors, pharmaceutical compositions and uses thereof
TWI721947B (zh) 2014-06-11 2021-03-21 美商基利法瑪席特有限責任公司 抗病毒化合物的固態形式
US10617675B2 (en) 2015-08-06 2020-04-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AU2017247798C1 (en) 2016-04-07 2020-08-27 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators
WO2017181383A1 (en) * 2016-04-21 2017-10-26 Merck Sharp & Dohme Corp. Hepatitis c virus inhibitors
KR102708681B1 (ko) 2018-02-13 2024-09-26 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
EP3781556B1 (en) 2018-04-19 2025-06-18 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
PL3820572T3 (pl) 2018-07-13 2024-02-26 Gilead Sciences, Inc. Inhibitory pd-1/pd-l1
CA3117199C (en) 2018-10-24 2024-03-19 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
US12497408B2 (en) 2021-05-21 2025-12-16 Gilead Sciences, Inc. Tetracyclic compounds and methods for the treatment of Zika virus infection
US12037340B2 (en) 2021-05-21 2024-07-16 Gilead Sciences, Inc. Pentacyclic derivatives as Zika virus inhibitors
CR20230576A (es) 2021-06-14 2024-04-05 Scorpion Therapeutics Inc Derivados de la urea que pueden ser utilizados para tratar el cáncer

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL127610C (es) * 1965-06-23
CH532608A (de) * 1969-12-17 1973-01-15 Ciba Geigy Ag Verfahren zur Herstellung von Bis-aroxazolyl-Verbindungen
CH553807A (de) * 1970-12-23 1974-09-13 Sandoz Ag Verfahren zur herstellung von dibenzthiophendioxidderivaten.
US3808206A (en) 1971-06-29 1974-04-30 Richardson Merrell Inc Bis-basic ketones of phenoxathiins and antiviral compositions thereof
US4371690A (en) * 1979-07-12 1983-02-01 E. I. Du Pont De Nemours And Company Heat-resistant rigid polymers from difunctional 9,10-dihydro-9,10-ethanoanthracenes
US5288914A (en) * 1984-08-27 1994-02-22 The Dow Chemical Company Poly(arylcyclobutenes)
US5288924A (en) * 1992-09-18 1994-02-22 Mobil Oil Corporation Process for starting up an olefin hydration reactor
US6054472A (en) 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
US5807876A (en) 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
EP0902782A1 (en) 1996-04-23 1999-03-24 Vertex Pharmaceuticals Incorporated Urea derivatives as inhibitors of impdh enzyme
DE69709671T2 (de) 1996-10-18 2002-08-22 Vertex Pharmaceuticals Inc., Cambridge Inhibitoren von serinproteasen, insbesondere von ns3-protease des hepatitis-c-virus
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
ATE244717T1 (de) 1997-03-14 2003-07-15 Vertex Pharma Inhibitoren des impdh-enzyms
US6010848A (en) 1997-07-02 2000-01-04 Smithkline Beecham Corporation Screening methods using an atpase protein from hepatitis C virus
JP4452401B2 (ja) 1997-08-11 2010-04-21 ベーリンガー インゲルハイム （カナダ） リミテッド Ｃ型肝炎ウイルス阻害ペプチドアナログ
CA2338490A1 (en) 1998-07-27 2000-02-10 Sergio Altamura Diketoacid-derivatives as inhibitors of polymerases
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
JP2002523371A (ja) 1998-08-21 2002-07-30 バイロファーマ・インコーポレイテッド ウイルス感染および関連疾患を治療または予防するための化合物、組成物および方法
CN1324250A (zh) 1998-09-04 2001-11-28 维洛药品公司 治疗或预防病毒感染及其所致疾病的方法
CN1324212A (zh) 1998-09-25 2001-11-28 维洛药品公司 治疗或预防病毒感染及有关疾病的方法
EA004141B1 (ru) 1999-03-19 2004-02-26 Вертекс Фармасьютикалз Инкорпорейтед Ингибиторы фермента impdh
US6242602B1 (en) * 1999-03-29 2001-06-05 Gentex Corporation One pot synthesis of 5,10-dihydrophenazine compounds and 5,10-substituted dihydrophenazines
US6566365B1 (en) 1999-11-04 2003-05-20 Biochem Pharma Inc. Method for the treatment of Flaviviridea viral infection using nucleoside analogues
EP1292310A1 (en) 2000-05-10 2003-03-19 SmithKline Beecham Corporation Novel anti-infectives
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
EP1256628A3 (en) 2001-05-10 2003-03-19 Agouron Pharmaceuticals, Inc. Hepatitis c virus (hcv) ns5b rna polymerase and mutants thereof
US6887877B2 (en) 2001-06-11 2005-05-03 Virochem Pharma Inc. Compounds and methods for the treatment or prevention of Flavivirus infections
EA007484B1 (ru) 2001-06-11 2006-10-27 Вирокем Фарма Инк. Соединения и способы лечения или предупреждения инфекций flavivirus
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
JP2003212846A (ja) * 2001-06-26 2003-07-30 Japan Tobacco Inc 縮合環化合物及びｃ型肝炎治療剤
CA2448737C (en) 2001-07-20 2010-06-01 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
EP2335700A1 (en) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
UA101465C2 (ru) * 2001-07-25 2013-04-10 Бёрингер Ингельхайм (Канада) Лтд. Использование индольного соединения для лечения или предупреждения инфицирования вирусом гепатита с
JP2005511573A (ja) 2001-11-02 2005-04-28 グラクソ　グループ　リミテッド Ｈｃｖ阻害剤としての４−（５−員）−ヘテロアリールアシルピロリジン誘導体
ATE370137T1 (de) 2001-11-02 2007-09-15 Glaxo Group Ltd 4-(6-gliedriger)-heteroaryl-acyl-pyrrolidin derivate als hcv-inhibitoren
JP2005511572A (ja) 2001-11-02 2005-04-28 グラクソ　グループ　リミテッド Ｈｃｖ阻害剤としてのアシルジヒドロピロール誘導体
DE602005017582D1 (en) 2004-01-30 2009-12-24 Medivir Ab Hcv ns-3 serine protease inhibitoren
US20080096848A1 (en) * 2004-09-29 2008-04-24 Cytovia Inc. Substituted N-Aryl-9-Oxo-9H-Fluorene-1-Carboxamides and Analogs as Activators of Caspases and Inducers of Apoptosis
US7355199B2 (en) * 2004-11-02 2008-04-08 E.I. Du Pont De Nemours And Company Substituted anthracenes and electronic devices containing the substituted anthracenes
DE102005022020A1 (de) * 2005-05-12 2006-11-23 Merckle Gmbh Dibenzocycloheptanverbindungen und pharmazeutische Mittel, welche diese Verbindungen enthalten
US8143288B2 (en) 2005-06-06 2012-03-27 Bristol-Myers Squibb Company Inhibitors of HCV replication
US7745636B2 (en) 2006-08-11 2010-06-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8329159B2 (en) * 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7759495B2 (en) * 2006-08-11 2010-07-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7659270B2 (en) * 2006-08-11 2010-02-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7741347B2 (en) * 2007-05-17 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7728027B2 (en) * 2007-08-08 2010-06-01 Bristol-Myers Squibb Company Process for synthesizing compounds useful for treating hepatitis C
US8629171B2 (en) * 2007-08-08 2014-01-14 Bristol-Myers Squibb Company Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt
US7704992B2 (en) * 2008-02-13 2010-04-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP5266786B2 (ja) * 2008-02-20 2013-08-21 富士ゼロックス株式会社 新規なフェノチアジン化合物
WO2010096462A1 (en) * 2009-02-17 2010-08-26 Enanta Pharmaceuticals, Inc Linked diimidazole derivatives
US9150554B2 (en) 2009-03-27 2015-10-06 Presidio Pharmaceuticals, Inc. Fused ring inhibitors of hepatitis C

Also Published As

Publication number Publication date
KR20110131312A (ko) 2011-12-06
BRPI1012282A2 (pt) 2015-09-22
CL2011002377A1 (es) 2012-01-20
EP2410843A1 (en) 2012-02-01
HK1166446A1 (en) 2012-11-02
JP2012522003A (ja) 2012-09-20
JP5735482B2 (ja) 2015-06-17
EA201190224A1 (ru) 2012-03-30
MX2011010132A (es) 2011-10-14
CO6450600A2 (es) 2012-05-31
AR076164A1 (es) 2011-05-26
CN102427726B (zh) 2014-10-08
CA2755658A1 (en) 2010-09-30
US20120040962A1 (en) 2012-02-16
US9150554B2 (en) 2015-10-06
CN102427726A (zh) 2012-04-25
SG174883A1 (en) 2011-11-28
EP2410843A4 (en) 2012-08-08
WO2010111534A1 (en) 2010-09-30
ZA201107753B (en) 2012-07-25
TW201038560A (en) 2010-11-01
AU2010229795A1 (en) 2011-10-13
IL215202A0 (en) 2011-12-29

Similar Documents

Publication Publication Date Title
PE20120773A1 (es) Anillos triciclicos fusionados sustituidos como inhibidores del virus de hepatitis c
CL2009000323A1 (es) Compuestos derivados de heterociclos no condensados sustituidos, inhibidores de la funcion de la proteina ns5a; composicion farmaceutica que los comprende; y su uso para tratar la infeccion del virus de la hepatitis c.
PE20131143A1 (es) Nuevas aminopirazoloquinazolinas
PE20120207A1 (es) Derivados de naftaleno, como inhibidores de hcv ns5a
AR078976A1 (es) Inhibidores heterociclicos de la proteina ns5a codificada por el virus de la hepatitis c(vhc), composiciones farmaceuticas que los comprenden y uso de los mismos para tratar infecciones por vhc
CL2009000324A1 (es) Compuestos derivados de heterociclos no condensados sustituidos, inhibidores de la funcion de la proteina ns5a; composicion farmaceutica que los comprende; y su uso para tratar la infeccion del virus de la hepatitis c.
CR20110049A (es) Derivados de benzazepina y su uso como antagonistas de histamina h3
CO6210721A2 (es) Acilaminopirazoles como inhibidores de fgfr
CO6400218A2 (es) Compuestos heterocíclicos antivirales
PE20090276A1 (es) Compuestos derivados de imidazoquinolina como moduladores de tlr7
CL2011001224A1 (es) Compuestos derivados de benzofurano-3-carboxamida; composicion farmaceutica que los comprende; y su uso en tratamiento del virus de la hepatitis c.
AR079634A1 (es) Inhibidores del virus de la hepatitis c
PE20090617A1 (es) Compuestos amino-5-[-4-(difluorometoxi)fenil]-5-fenilimidazolona para la inhibicion de -secretasa
CO6491049A2 (es) Inhibidores de los virus flaviviridae
AR073574A1 (es) Inhibidores heterociclicos de los receptores de histamina para el tratamiento de una enfermedad
AR076067A1 (es) Composiciones y metodos para modular la senda de senalizacion de wnt
PE20081447A1 (es) Compuestos y composiciones como inhibidores de la proteina cinasa
AR079334A1 (es) Derivados de oxazin amino
PE20120305A1 (es) Compuestos heterociclicos derivados de benzotiazol y tetrahidroquinolina como inhbidores de bcl-2 y bcl-xl
CL2007003250A1 (es) Compuestos derivados de isoquinolina, inhibidores del virus de hepatitis c; composicion farmaceutica; y uso para el tratamiento de una infeccion por vhc.
CL2013001141A1 (es) Compuestos derivados de heterociclos condensados, inhibidores del virus de la hepatitis c; composicion farmaceutica que los contiene; y su uso para el tratamiento de la infeccion por el virus de la hepatitis c.
UY30127A1 (es) Derivados de acidos antranilicos fenoxi y feniltio, composiciones farmaceuticas que los contienen y su uso.
CL2008003511A1 (es) Compuestos derivados nucleotidicos, inhibidores de polimerasa ns5b del virus de la hepatitis c; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c.
LT3758708T (lt) Farmacinės kompozicijos, apimančios (2s)-{(1s)-1-ciano-2-[4-(3-metil-2-okso-2,3-dihidro-1,3-benzoksazol-5-il)fenil]etil}-1,4-oksazepan-2-karboksamidą
AR080596A1 (es) Compuestos alquilamido y composiciones farmaceuticas

Legal Events

Date Code Title Description
FC Refusal